08/11/2025
Allevia Lifesciences and Provectus Therapeutics have joined forces to redefine precision oncology, bringing Single-Cell AI Drug Screening to the forefront of personalized cancer care.
We’re excited to introduce a next-generation platform for precision oncology, Single-Cell AI Drug Screening, developed by Provectus Therapeutics and commercially deployed by Allevia Lifesciences.
This joint solution enables:
🔬 Functional drug sensitivity profiling at the single-cell level
⚡ Rapid turnaround (results in 2-5 days)
🎯 Personalized treatment recommendations for breast cancer patients
🌐 Expansion underway for lung and other cancer types
By combining microfluidics, high-throughput imaging, and AI-powered analytics, the platform screens over 1 million individual tumour cells per test, empowering oncologists to select therapies based on real-time phenotypic responses, not just genetic markers.
📍 Testing conducted at Hong Kong Science Park
📞 Clinical access available via Allevia’s oncology network
This partnership reflects a shared commitment to translational innovation, clinical accessibility, and data-driven cancer care, especially for patients with relapsed, refractory, or metastatic disease.
👉 If you're an oncologist, surgeon, researcher, or patient advocate interested in this platform, reach out at enquiry@alleviahk.com.